PMID- 21091356
OWN - NLM
STAT- MEDLINE
DCOM- 20110314
LR  - 20181201
IS  - 1525-6006 (Electronic)
IS  - 1064-1963 (Linking)
VI  - 32
IP  - 8
DP  - 2010
TI  - Pentosan reduces osteonecrosis of femoral head in SHRSP.
PG  - 511-6
LID - 10.3109/10641963.2010.496511 [doi]
AB  - Increased oxidative stress is considered one of the main causes of 
      steroid-induced osteonecrosis of the femoral head (ONFH). The aim of this study 
      was to evaluate the effects of a steroid hormone and pentosan polysulfate sodium 
      (pentosan), a heparin analog, in stroke-prone spontaneously hypertensive rats 
      (SHRSP) as a model of ONFH. One hundred twenty-three 13-week-old male SHRSP/Izm 
      rats were divided into four groups: a control group (group C), 
      pentosan-administered group (group P), steroid-administered group (group S), and 
      group administered pentosan plus steroid (group PS). Methylprednisolone acetate, 
      as the steroid hormone, at a dose of 4 mg (15 mg/kg) was administered at 15 weeks 
      of age. Pentosan at a dose of 3 mg/day/kg was continuously administered 
      intraperitoneally from 13 weeks of age for 4 weeks. Rats were sacrificed at 17 
      weeks of age, and heart blood and both femora were collected. Triglyceride levels 
      were significantly lower in group PS than in group S, indicating that pentosan 
      improves lipid metabolism. The incidence of histologic ONFH was significantly 
      lower in group P, at 14.8% (10/71 femoral heads), than in group C, at 30.4% 
      (17/56 femoral heads), and significantly lower in group PS, at 40.8% (29/71 
      femoral heads), than in group S, at 91.3% (42/46 femoral heads), indicating that 
      pentosan markedly inhibits ONFH. Immunohistochemical staining for oxidative 
      stress showed that the stainability was significantly lower in group PS than in 
      group S. Pentosan seems to reduce the incidence of ONFH in SHRSP by improving 
      lipid metabolism and decreasing oxidative stress.
FAU - Miyata, Noriaki
AU  - Miyata N
AD  - Department of Orthopedic Surgery, Nagasaki University, Graduate School of 
      Biomedical Sciences.
FAU - Kumagai, Kenji
AU  - Kumagai K
FAU - Osaki, Makoto
AU  - Osaki M
FAU - Murata, Masakazu
AU  - Murata M
FAU - Tomita, Masato
AU  - Tomita M
FAU - Hozumi, Akira
AU  - Hozumi A
FAU - Nozaki, Yoshihiro
AU  - Nozaki Y
FAU - Niwa, Masami
AU  - Niwa M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
RN  - 37300-21-3 (Pentosan Sulfuric Polyester)
RN  - 43502P7F0P (Methylprednisolone Acetate)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Animals
MH  - Blood Coagulation/drug effects
MH  - Disease Models, Animal
MH  - Femur Head Necrosis/blood/chemically induced/metabolism/*prevention & control
MH  - Lipid Metabolism/drug effects
MH  - Male
MH  - Methylprednisolone/analogs & derivatives/toxicity
MH  - Methylprednisolone Acetate
MH  - Oxidative Stress/drug effects
MH  - Pentosan Sulfuric Polyester/*therapeutic use
MH  - Rats
MH  - Rats, Inbred SHR
EDAT- 2010/11/26 06:00
MHDA- 2011/03/15 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/03/15 06:00 [medline]
AID - 10.3109/10641963.2010.496511 [doi]
PST - ppublish
SO  - Clin Exp Hypertens. 2010;32(8):511-6. doi: 10.3109/10641963.2010.496511.